Kesol (Budesonide)

Budesonide binds to glucocorticoid receptors inside nasal epithelial cells, altering gene transcription. This suppresses the production of inflammatory cytokines and chemokines, decreasing immune‑cell infiltration and swelling of the nasal mucosa, which alleviates the symptoms of allergic rhinitis and nasal polyps.

The dose of Kesol is individualized by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and response to therapy. Patients should follow the prescriber’s instructions and the product’s labeling for the number of sprays per nostril and frequency of use.

Safety data for budesonide nasal spray in pregnancy are limited, so it should be used only if the potential benefit outweighs any risk to the fetus. During breastfeeding, budesonide may be excreted in milk; clinicians should weigh the benefits against possible effects on the infant.

To order Kesol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Kesol’s active ingredient, budesonide, offers high topical potency with low systemic absorption, similar to other second‑generation nasal corticosteroids such as fluticasone and mometasone. Compared with older agents, budesonide generally provides effective symptom control with a favorable safety profile when used as directed.

Kesol should be stored at room temperature, away from direct sunlight and moisture. Keep the spray in its original packaging, close the cap tightly after each use, and avoid exposing it to extreme heat or humidity to maintain product stability.

Kesol is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include fungal infection of the nasal mucosa, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, and hypersensitivity reactions such as angioedema. Patients should seek medical attention promptly if they experience unusual bleeding, signs of infection, or allergic symptoms.

Kesol should be avoided in individuals with known hypersensitivity to budesonide or any component of the formulation. Patients with active untreated nasal infections, recent nasal surgery or trauma, and those receiving systemic corticosteroids without medical supervision should discuss alternative therapies with their clinician.